Similar Search Results

Results of Survey of Economics Professors on Immigration, Drug, and Pharmaceutical Policies

Briggeman, Jason - 2017

We conducted a survey by mail in 2013 of randomly selected economics professors in the United States about the welfare effects of three proposed policy reforms. We received back 574 completed surveys (a 19 percent response rate). A large majority supported a reform to increase immigration into...

Persistent link: https://www.econbiz.de/10012944740

Regulatory Review Time and Pharmaceutical R&D

Chorniy, Anna - 2019

In the United States, all newly developed drugs undergo a lengthy review process conducted by the Federal Food and Drug Administration (FDA). These regulatory delays are costly for drug manufacturers and patients. We collected data on review times of drugs approved between 1999 and 2005 and...

Persistent link: https://www.econbiz.de/10012865204

Pharmaceutical Opioid Marketing and Physician Prescribing Behavior

Beilfuss, Svetlana - 2019

Physicians' relationships with the pharmaceutical industry have recently come under public scrutiny, particularly in the context of opioid drug prescribing. This study examines the effect of doctor-industry marketing interactions on subsequent prescribing patterns of opioids using linked...

Persistent link: https://www.econbiz.de/10012871515

Pharmaceutical Antitrust : What the Trump Administration Can Do

Carrier, Michael A. - 2016

Drug prices are in the news. “Pharma Bro” Martin Shkreli increased the price of Daraprim, a treatment for fatal parasitic infections, by 5000%. Mylan found itself on the hot seat for raising the price of the anaphylaxis-treating EpiPen 15 times in 7 years, resulting in a 400% increase to...

Persistent link: https://www.econbiz.de/10012978113

Free Movement and Competition in the European Market for Pharmaceuticals

Caro de Sousa, Pedro - 2016

.This chapter will provide an overview of free movement cases on pharmaceuticals, with a view to frame such case law within the … section will provide an overview of the structure of the European market for pharmaceuticals, including the basic European … regulatory framework; a second section will review the case law on free movement and pharmaceuticals; and a last section will …

Persistent link: https://www.econbiz.de/10012980141

Double Patenting : Follow-On Pharmaceutical Patents that Suppress Competition

Rogers, Douglas L. - 2016

Prices for pharmaceutical products over the last 10 years have skyrocketed, increasing far more rapidly than the general cost of living. This article argues there should be greater competition for the production of follow-on drugs through the strengthening of the double patenting prohibition:...

Persistent link: https://www.econbiz.de/10013002400

Ask Your Doctor or Pharmacist! On the Effect of Self-Dispensing Physicians on Pharmaceutical Coverage

Bannert, Matthias - 2015

In most developed countries drugs are dispensed to patients through physicians and pharmacists. This paper studies the effects of allowing doctors to directly dispense drugs to patients (self-dispensation) on pharmaceutical coverage. We use a Swiss dataset in our empirical analysis because...

Persistent link: https://www.econbiz.de/10013021080

Launch Decisions of Pharmaceutical Companies

Civan, Abdulkadir - 2016

This paper models the launch decision of pharmaceutical companies in regard to new drugs and country markets. New drugs are launched with a delay or not launched at all in many countries. Considering that many of these new drugs would have created health benefits to the patients, there seems to...

Persistent link: https://www.econbiz.de/10012993196

Risky Business : Should the FDA Pay Attention to Drug Prices?

Hyman, David A. - 2018

The Food and Drug Administration currently does not monitor drug prices. As FDA leaders note, the agency's responsibility is for drug safety and efficacy, and besides they do not want to become embroiled in drug pricing controversies. However, monitoring drug pricing can be useful beyond any...

Persistent link: https://www.econbiz.de/10012923980

Conflicts of Interest on Expert Committees : The Case of FDA Drug Advisory Committees

Cooper, James C. - 2018

Governments and firms often use committees of experts to help them make complexdecisions, but conflicts of interest could bias experts' recommendations. We focus on whetherfinancial ties to drug companies bias FDA drug advisory committee (AC) members' voting ondrug approval recommendations. We...

Persistent link: https://www.econbiz.de/10012934325